Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Oligosaccharides, particularly prebiotic oligosaccharides such as fructooligosaccharides (FOS), galactooligosaccharides (GOS), and inulin, have been investigated for their potential to support colitis, especially ulcerative colitis and experimental models of inflammatory bowel disease (IBD). The scientific rationale centers around their ability to modulate gut microbiota composition by promoting the growth of beneficial bacteria (e.g., Bifidobacteria, Lactobacilli), which can improve intestinal barrier function and reduce inflammation. Animal studies have shown that supplementation with certain oligosaccharides can reduce colonic inflammation, decrease pro-inflammatory cytokines, and improve histological outcomes. Some small human studies and pilot clinical trials have reported improvements in symptoms and inflammatory markers in patients with ulcerative colitis who consumed prebiotic oligosaccharides. However, the evidence is not uniformly robust. Most clinical trials to date have been small, with heterogeneity in the type, dose, and duration of oligosaccharide used. Meta-analyses and systematic reviews suggest potential benefits but emphasize the need for larger, well-controlled studies to confirm efficacy and establish optimal formulations. Thus, while there is a plausible scientific basis and preliminary evidence supporting the use of oligosaccharides as adjunct therapy in colitis, the overall quality and consistency of the evidence is moderate rather than high.

More about Oligosaccharide (unspecified)
More about Colitis

Other ingredients used for Colitis

Other health conditions supported by Oligosaccharide (unspecified)

Products containing Oligosaccharide (unspecified)